Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Name: Kaimen Rigor review — Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Item: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Rating: 96
Author: Alpha1

Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Read full text (PMC)

DOI

10.1056/NEJMoa2411680

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/14555da8-cb24-40aa-9957-ff152bfe2be6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/14555da8-cb24-40aa-9957-ff152bfe2be6/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

1c29182a573ecc5bf631db950c2564a3c93f021c4fb3ae4a96214779f638c70b

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Paper source

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial with clear randomization, stratification, power analysis, and ethical approvals. The main methodological weakness is the lack of a formal data availability statement and unspecified statistical software, which are minor reporting gaps. The statistical analyses are appropriate and the reported tests recomputed consistently.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence to reconcile. The study is an interventional trial; animal-related and bench-resource sub-criteria were marked not applicable. The statistics verification covered only 5 tests with test statistics/CI; other p-values (e.g., threshold-only) were not machine-verified and remain unverified, not confirmed.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

None found

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Checked — nothing surfaced.

7 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies on blinatumomab in relapsed pediatric B-ALL and adult E1910, and identifies the knowledge gap for newly diagnosed pediatric patients. The rationale is logical: blinatumomab improves outcomes in relapsed disease, so it may benefit newly diagnosed patients. Limitations of prior work are implicitly addressed by noting the need for pediatric-specific data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

“Blinatumomab improves outcomes among children with relapsed B-ALL. – Among adults, the E1910 study found that adding blinatumomab to standard chemotherapy increased relapse-free and overall survival among adults with newly diagnosed disease.”

Introduction ¶1Find in source

“Whether incorporating blinatumomab also improves outcomes among children with newly diagnosed B-ALL was unknown.”

Introduction ¶1Find in source

absence[Introduction]

Limitations of prior work are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

“Whether incorporating blinatumomab also improves outcomes among children with newly diagnosed B-ALL was unknown.”

Introduction ¶1Find in source

absence[Introduction]

Limitations of prior work are not explicitly discussed.

Randomization was central, 1:1, stratified by risk group and Down syndrome status. The trial was open-label with a stated rationale (blinding infeasible for an infusion-based therapy). Power analysis was pre-specified with target accrual and effect size. Inclusion/exclusion criteria are detailed. The analysis population (ITT) and missing data handling are described. Controls are the chemotherapy-alone arms. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analysis plans.

Evidence

“The 1:1 randomization was conducted centrally and stratified by SR-Avg non-Down syndrome, SR-Avg Down syndrome, and SR-High.”

MethodsFind in source

“Neither providers nor patients were blinded.”

MethodsFind in source

“Using a two-sided α of 5%, the trial would have 81% power to detect a 34.5% improvement [hazard ratio (HR)=0.655] in disease-free survival, with 194 events at final analysis.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analysis plans.

Evidence

“The 1:1 randomization was conducted centrally and stratified by SR-Avg non-Down syndrome, SR-Avg Down syndrome, and SR-High.”

MethodsFind in source

“Neither providers nor patients were blinded.”

MethodsFind in source

“Using a two-sided α of 5%, the trial would have 81% power to detect a 34.5% improvement [hazard ratio (HR)=0.655] in disease-free survival, with 194 events at final analysis.”

Statistical analysisFind in source

Sex, age, race/ethnicity, and key disease features are reported in Table 1. Both sexes are enrolled, so sex justification is not applicable. Age and health status are reported. Species/strain and housing are not applicable for a human trial. Demographics are comprehensive.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported for the randomized cohort.

Evidence

“The median age of randomized patients was 4.3 years [interquartile range (IQR) 2.8–6.4]; 52.6% were male, 26% were Hispanic and 5% were non-Hispanic Black.”

ResultsFind in source

“Table 1. Characteristics of the Patients who Underwent Randomization”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported for the randomized cohort.

Evidence

“Median age (range) – yr | 4.3 (1.0–10.0) | 4.0 (1.0–9.9) | 4.2 (1.0–10.0) | 4.2 (1.1–9.9) | 4.6 (1.0–10.0) | 4.4 (1.0–10.0)”

Table 1Find in source

“Hispanic | 104 (24.9%) | 100 (24.0%) | 204 (24.4%) | 84 (27.6%) | 84 (27.9%) | 168 (27.8%)”

Table 1Find in source

The protocol was approved by the NCI Central IRB and local IRBs. Written informed consent from guardians and assent as necessary are described. Regulatory compliance is implied through the approval process. The trial is registered (NCT03914625).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“The protocol was approved by the pediatric Central Institutional Review Board (CIRB) of the NCI and local IRBs.”

MethodsFind in source

“Each patient’s legal guardian provided written informed consent; assent was obtained as necessary.”

MethodsFind in source

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“The protocol was approved by the pediatric Central Institutional Review Board (CIRB) of the NCI and local IRBs.”

MethodsFind in source

“Each patient’s legal guardian provided written informed consent; assent was obtained as necessary.”

MethodsFind in source

Blinatumomab is named with manufacturer (Amgen) and dosing regimen. The trial is a drug trial, so bench reagents are not applicable. Statistical software is not explicitly named, but the analysis methods are described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (blinatumomab) is adequately identified, and key assays are described.

Evidence

“Patients assigned to experimental arms received two cycles of continuous intravenous infusion blinatumomab 15µg/m 2 /day (max 28µg/day) for 28 days”

MethodsFind in source

“sequencing MRD was measured using ClonoSEQ B-cell clonality/tracking assays.”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

PASSReviewer 2· 90% conf

The investigational product (blinatumomab) is adequately identified, and software tools are named.

Evidence

“Patients assigned to experimental arms received two cycles of continuous intravenous infusion blinatumomab 15µg/m 2 /day (max 28µg/day) for 28 days”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

The primary analysis used RMST due to nonproportionality, with a 1-sided stratified log-rank p=0.00004. Effect sizes are reported as RMST differences with 95% CIs. Tests are named (log-rank, Cox, Fisher's exact). Assumptions are handled by design (RMST for nonproportionality). Software is not identified, but this is minor. Data presentation includes Kaplan-Meier curves and tables with per-group Ns. Mathematical plausibility checks are not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Adding blinatumomab significantly improved disease-free survival [RMST difference 72 days, 95% CI 36–108 days, 1-sided stratified log-rank p=0.00004]”

ResultsFind in source

“disease-free survival was compared between the chemotherapy and the chemotherapy plus blinatumomab groups using a log-rank test stratified by non-Down syndrome SR-Avg vs. Down syndrome SR-Avg vs. SR-High.”

Statistical analysisFind in source

absence[Methods, Statistical Analysis]

Software is not identified.

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“1-sided stratified log-rank p=0.00004”

ResultsFind in source

“RMST difference 72 days, 95% CI 36–108 days”

ResultsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not named.

The paper states that the protocol is available at NEJM.org, but does not provide a clear data availability statement for the clinical data. No repository deposit or accession numbers are provided for the trial data. No custom code is mentioned, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no code is shared.

Evidence

“Full statistical analysis plans are detailed in the protocol, available at NEJM.org (http://www.nejm.org/) .”

Statistical analysisFind in source

absence[Entire paper]

No data repository deposit is mentioned.

WARNReviewer 2· 80% conf

Data availability is not explicitly stated; the trial is registered and protocol is available, but no data sharing statement is present.

Evidence

absence[Entire paper]

No data availability statement is present.

“Detailed eligibility criteria are included in the trial protocol (available NEJM.org (http://www.nejm.org/) ).”

MethodsFind in source

The trial is registered (NCT03914625). Methods are detailed. All outcomes are reported, including negative toxicity findings. Limitations are discussed (e.g., post-hoc subgroup analyses, lack of CNS activity). Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, funding, and limitations discussed.

Evidence

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

“Though post-hoc, subgroup analyses show consistency in the magnitude of effect across leukemia cytogenetic risk group”

Discussion ¶4Find in source

“This study was supported by grants from the National Institutes of Health/National Cancer Institute (U10CA180899; U20CA180886) and from the St. Baldrick’s Foundation.”

FundingFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, funding, and limitations discussed.

Evidence

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

“This study was supported by grants from the National Institutes of Health/National Cancer Institute (U10CA180899; U20CA180886) and from the St. Baldrick’s Foundation.”

Supplementary materialFind in source

absence[Methods]

No reporting guideline is mentioned.

Registered (3 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 41 references by DOI: 36 verified — 5 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and the reported statistics are consistent with the subset that could be recomputed. An informed reader should weigh the absence of a formal data availability statement and the unspecified statistical software as minor transparency gaps; no erratum appears warranted based on the integrity checks, which found no internal contradictions or unsupported claims.

1.
HIGHdata code
Add a formal data availability statement in the Methods or a dedicated section, specifying how de-identified individual patient data can be accessed (e.g., via a managed access process through the COG data sharing committee) with conditions and timeframe.
The paper currently only mentions protocol availability, which is inadequate for a data-driven clinical trial and would be flagged by reviewers.
2.
HIGHstatistics
Identify the statistical software (e.g., SAS version, R version) used for analyses in the Statistical Analysis section.
Reproducibility requires naming the software and version; both reviewers noted this omission.
3.
MEDIUMreporting
Reference the CONSORT reporting guideline in the Methods or provide a completed CONSORT checklist as supplementary material.
Explicitly citing CONSORT enhances transparency and is expected for a randomized trial.
4.
MEDIUMdata code
Provide accession numbers for any genomic or sequencing data generated (e.g., HTS MRD data) if deposited in a public repository.
Accession numbers enable verification and reuse of sequencing data.
5.
MEDIUMdata code
Clarify the data sharing policy for the trial protocol and statistical analysis plan, possibly with a link or DOI to a public repository.
A clear policy improves transparency and reader trust.
6.
LOWdata code
If custom code was used for analyses, share it in a public repository (e.g., GitHub) with a DOI.
Sharing code facilitates full reproducibility.
7.
LOWcopyedit
Fix the misspelling 'Treatement-related mortality' to 'Treatment-related mortality' in Discussion paragraphs 1 and 2.
Typos in a high-profile journal undermine professionalism.
8.
LOWcopyedit
Consider reporting the primary p-value as p<0.0001 or with consistent significant figures across the paper.
The p-value 0.00004 is reported with 5 decimals while others use 2-3; consistency improves clarity.
9.
LOWcopyedit
Clarify 'alpha-t square spending functions' to 'alpha-spending functions' in Methods, Statistical Analysis.
The current phrasing is unclear and likely a typo.
10.
LOWcopyedit
Ensure consistent naming of the experimental arm (e.g., 'blinatumomab' vs 'blinatumomab and chemotherapy') throughout the abstract and results.
Consistent terminology avoids confusion.

Full text (38,421 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Read full text (PMC)

DOI

10.1056/NEJMoa2411680

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/14555da8-cb24-40aa-9957-ff152bfe2be6" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/14555da8-cb24-40aa-9957-ff152bfe2be6/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 2 high issues for “Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

1c29182a573ecc5bf631db950c2564a3c93f021c4fb3ae4a96214779f638c70b

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

101ArithmeticNumerical inconsistencies 02OverreachNone found 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

None found

Checked — nothing surfaced.

7 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the study.

Evidence

Introduction ¶1Find in source

“Whether incorporating blinatumomab also improves outcomes among children with newly diagnosed B-ALL was unknown.”

Introduction ¶1Find in source

absence[Introduction]

Limitations of prior work are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

“Whether incorporating blinatumomab also improves outcomes among children with newly diagnosed B-ALL was unknown.”

Introduction ¶1Find in source

absence[Introduction]

Limitations of prior work are not explicitly discussed.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analysis plans.

Evidence

“The 1:1 randomization was conducted centrally and stratified by SR-Avg non-Down syndrome, SR-Avg Down syndrome, and SR-High.”

MethodsFind in source

“Neither providers nor patients were blinded.”

MethodsFind in source

“Using a two-sided α of 5%, the trial would have 81% power to detect a 34.5% improvement [hazard ratio (HR)=0.655] in disease-free survival, with 194 events at final analysis.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified analysis plans.

Evidence

“The 1:1 randomization was conducted centrally and stratified by SR-Avg non-Down syndrome, SR-Avg Down syndrome, and SR-High.”

MethodsFind in source

“Neither providers nor patients were blinded.”

MethodsFind in source

“Using a two-sided α of 5%, the trial would have 81% power to detect a 34.5% improvement [hazard ratio (HR)=0.655] in disease-free survival, with 194 events at final analysis.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported for the randomized cohort.

Evidence

“The median age of randomized patients was 4.3 years [interquartile range (IQR) 2.8–6.4]; 52.6% were male, 26% were Hispanic and 5% were non-Hispanic Black.”

ResultsFind in source

“Table 1. Characteristics of the Patients who Underwent Randomization”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported for the randomized cohort.

Evidence

“Median age (range) – yr | 4.3 (1.0–10.0) | 4.0 (1.0–9.9) | 4.2 (1.0–10.0) | 4.2 (1.1–9.9) | 4.6 (1.0–10.0) | 4.4 (1.0–10.0)”

Table 1Find in source

“Hispanic | 104 (24.9%) | 100 (24.0%) | 204 (24.4%) | 84 (27.6%) | 84 (27.9%) | 168 (27.8%)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“The protocol was approved by the pediatric Central Institutional Review Board (CIRB) of the NCI and local IRBs.”

MethodsFind in source

“Each patient’s legal guardian provided written informed consent; assent was obtained as necessary.”

MethodsFind in source

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are clearly documented.

Evidence

“The protocol was approved by the pediatric Central Institutional Review Board (CIRB) of the NCI and local IRBs.”

MethodsFind in source

“Each patient’s legal guardian provided written informed consent; assent was obtained as necessary.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (blinatumomab) is adequately identified, and key assays are described.

Evidence

“Patients assigned to experimental arms received two cycles of continuous intravenous infusion blinatumomab 15µg/m 2 /day (max 28µg/day) for 28 days”

MethodsFind in source

“sequencing MRD was measured using ClonoSEQ B-cell clonality/tracking assays.”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

PASSReviewer 2· 90% conf

The investigational product (blinatumomab) is adequately identified, and software tools are named.

Evidence

“Patients assigned to experimental arms received two cycles of continuous intravenous infusion blinatumomab 15µg/m 2 /day (max 28µg/day) for 28 days”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Adding blinatumomab significantly improved disease-free survival [RMST difference 72 days, 95% CI 36–108 days, 1-sided stratified log-rank p=0.00004]”

ResultsFind in source

Statistical analysisFind in source

absence[Methods, Statistical Analysis]

Software is not identified.

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“1-sided stratified log-rank p=0.00004”

ResultsFind in source

“RMST difference 72 days, 95% CI 36–108 days”

ResultsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not named.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no code is shared.

Evidence

“Full statistical analysis plans are detailed in the protocol, available at NEJM.org (http://www.nejm.org/) .”

Statistical analysisFind in source

absence[Entire paper]

No data repository deposit is mentioned.

WARNReviewer 2· 80% conf

Data availability is not explicitly stated; the trial is registered and protocol is available, but no data sharing statement is present.

Evidence

absence[Entire paper]

No data availability statement is present.

“Detailed eligibility criteria are included in the trial protocol (available NEJM.org (http://www.nejm.org/) ).”

MethodsFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, funding, and limitations discussed.

Evidence

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

“Though post-hoc, subgroup analyses show consistency in the magnitude of effect across leukemia cytogenetic risk group”

Discussion ¶4Find in source

“This study was supported by grants from the National Institutes of Health/National Cancer Institute (U10CA180899; U20CA180886) and from the St. Baldrick’s Foundation.”

FundingFind in source

PASSReviewer 2· 90% conf

The manuscript is transparent with trial registration, funding, and limitations discussed.

Evidence

“ClinicalTrials.gov (http://www.clinicaltrials.gov/) number NCT03914625”

AbstractFind in source

“This study was supported by grants from the National Institutes of Health/National Cancer Institute (U10CA180899; U20CA180886) and from the St. Baldrick’s Foundation.”

Supplementary materialFind in source

absence[Methods]

No reporting guideline is mentioned.

Registered (3 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 41 references by DOI: 36 verified — 5 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Add a formal data availability statement in the Methods or a dedicated section, specifying how de-identified individual patient data can be accessed (e.g., via a managed access process through the COG data sharing committee) with conditions and timeframe.
The paper currently only mentions protocol availability, which is inadequate for a data-driven clinical trial and would be flagged by reviewers.
2.
HIGHstatistics
Identify the statistical software (e.g., SAS version, R version) used for analyses in the Statistical Analysis section.
Reproducibility requires naming the software and version; both reviewers noted this omission.
3.
MEDIUMreporting
Reference the CONSORT reporting guideline in the Methods or provide a completed CONSORT checklist as supplementary material.
Explicitly citing CONSORT enhances transparency and is expected for a randomized trial.
4.
MEDIUMdata code
Provide accession numbers for any genomic or sequencing data generated (e.g., HTS MRD data) if deposited in a public repository.
Accession numbers enable verification and reuse of sequencing data.
5.
MEDIUMdata code
Clarify the data sharing policy for the trial protocol and statistical analysis plan, possibly with a link or DOI to a public repository.
A clear policy improves transparency and reader trust.
6.
LOWdata code
If custom code was used for analyses, share it in a public repository (e.g., GitHub) with a DOI.
Sharing code facilitates full reproducibility.
7.
LOWcopyedit
Fix the misspelling 'Treatement-related mortality' to 'Treatment-related mortality' in Discussion paragraphs 1 and 2.
Typos in a high-profile journal undermine professionalism.
8.
LOWcopyedit
Consider reporting the primary p-value as p<0.0001 or with consistent significant figures across the paper.
The p-value 0.00004 is reported with 5 decimals while others use 2-3; consistency improves clarity.
9.
LOWcopyedit
Clarify 'alpha-t square spending functions' to 'alpha-spending functions' in Methods, Statistical Analysis.
The current phrasing is unclear and likely a typo.
10.
LOWcopyedit
Ensure consistent naming of the experimental arm (e.g., 'blinatumomab' vs 'blinatumomab and chemotherapy') throughout the abstract and results.
Consistent terminology avoids confusion.

Full text (38,421 chars)Analyzed: Aug 16, 2026